I'm LongbridgeAI. Here is the key information I extracted- CGN Mining reported a net loss of 80,000,000 HKD due to lower uranium sales, while China Pacific Insurance achieved a net profit of 53,505,000,000 RMB with a 19.0% year-on-year growth.…
According to recent corporate filings and industry data, multiple Hong Kong-listed companies across healthcare, energy, and consumer sectors are undergoing notable operational shifts. The data indicates divergent performance trajectories in 2026, with several firms targeting structural improvements through core project advancements.
CGN Mining (1164.HK)
CGN Mining saw a recent intraday rebound in its stock performance, driven by long-term contract prices for natural uranium reaching historical highs. According to its interim results announced in August 2026, the company reported an attributable loss of approximately HKD 80 million, representing an 18% widening year-over-year. The financial pressure was largely attributed to declining sales volumes and rising costs. However, analysts expect the company to benefit from the upward cycle in uranium prices.
Keymed Biosciences (6700.HK)
Keymed Biosciences has made material progress in its innovative pipeline. The company officially initiated its A-share listing process, completing the STAR Market registration in August 2026. Its core product has been approved for multiple indications and included in the national reimbursement drug list. Furthermore, an exclusive licensing deal with AstraZeneca is projected to generate over USD 1.1 billion in revenue for the firm.
Star Plus Legend (6683.HK)
Star Plus Legend is expanding its footprint through acquisitions and cross-industry partnerships. In September 2025, the company announced the acquisition of a roughly 1.17% stake in the National Stadium operation company. Subsequently, it became a strategic shareholder of Korean entertainment agency Galaxy. The company is also collaborating with Unitree Robotics to develop IP-driven consumer products, aiming to boost its new retail operations.
Biocytogen (2315.HK)
Biocytogen continues to scale its drug discovery platforms. As of July 2025, the company had completed over 5,300 drug evaluation projects for nearly 900 global pharmaceutical firms and research institutions. The company is targeting a dual-listing structure by planning an IPO on the STAR Market, which is expected to support its global initiatives.
China Pacific Insurance (0381.HK)
China Pacific Insurance maintained robust financial metrics. According to its 2025 earnings report, total revenue reached RMB 435.15 billion, up 7.7% year-over-year, while net income rose 19.0% to RMB 53.50 billion. The insurer continues to scale its green investments, with total commitments exceeding RMB 300 billion, according to company statements.
Concord New Energy (2618.HK)
Concord New Energy is actively expanding its operational scale. As of June 30, 2026, the group's attributable installed capacity surpassed 5GW globally. The company also listed on the main board of the Singapore Exchange in January 2026. Despite substantial pricing pressure in solar power generation, the firm continues to invest in wind and energy storage infrastructure.
Yunkang Group (6871.HK)
Yunkang Group is advancing the digitalization of its medical testing services. In July 2026, the company announced an AI-integrated pathology solution intended to improve diagnostic efficiency across the entire workflow. The firm continues to hold the largest number of dual-certified independent clinical laboratories in China.
Star CM (3952.HK)
Star CM is facing severe operational headwinds. Due to operational difficulties, its affiliated channels Xing Kong and Channel [V] sequentially announced the suspension of satellite transmission services in May 2026. The company's total revenue has shrunk by over 50% compared to 2019 levels, reflecting structural challenges in traditional television broadcasting.
Sun Hing Vision (1609.HK)
Sun Hing Vision reported margin pressures in its latest financial disclosure. For the year ended March 31, 2026, total revenue grew 7.55% year-over-year to HKD 891 million, but the loss attributable to shareholders widened to HKD 45.9 million. The company continues to rely on its manufacturing network in mainland China and joint ventures in Vietnam to serve global brands.
Wasion Holdings (0894.HK)
Wasion Holdings is currently navigating a period of operational adjustment. The company has not disclosed detailed operational metrics for the latest quarter in 2026 but remains focused on maintaining its market positioning amid ongoing industry volatility.
This article does not constitute investment advice.
